Advances of human papillomavirus therapeutic vaccine
10.3760/cma.j.issn.1673-422X.2017.07.012
- VernacularTitle:人乳头瘤病毒治疗性疫苗的研究进展
- Author:
Yinghai WANG
;
Hongping ZHANG
;
Jing YU
;
Chunlin LI
;
Yihan LU
- Keywords:
Papillomavirus vaccine;
Uterine cervical neoplasms
- From:
Journal of International Oncology
2017;44(7):526-530
- CountryChina
- Language:Chinese
-
Abstract:
Human papillomavirus continuous (HPV) infection is an essential factor to induce cervical intraepithelial neoplasia and cervical cancer.Treating HPV infection is considered as a starting point to develop an effective therapeutic vaccine, which is a new strategy for prevention and treatment of cervical cancer.In recent years, development and trials of therapeutic HPV vaccine have made great progress.Selection of vectors, utilization of adjuvants, synthesis of fusion proteins and chimeric proteins have been widely applied to research to enhance vaccine immunogenicity, to increase vaccination safety, to reduce the side effect and so on.The clinical trial results are encouraging: various types of vaccines can induce a specific immune response with good tolerance.However, numerous studies are still required to obtain further success.In addition, HPV exists in various forms, thus it is also the focus of study to expand the range of action and reduce immune escape.
